Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ropinirole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.95 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.95 |
| ▸ | DRD1 | P21728 | 2/20 | 0.95 |
| ▸ | DRD5 | P21918 | 2/20 | 0.95 |
| ▸ | HTR1A | P08908 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ropinirole SCHEMBL29374522 | 0.97 | DRD2 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL35212 | 0.97 | DRD2 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL4623647 | 0.96 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL1787068 | 0.96 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL16044076 | 0.96 | DRD2 (0.97) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL29278850 | 0.96 | DRD2 (0.97) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL40760 | 0.96 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL29366889 | 0.96 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL28937023 | 0.95 | DRD2 (0.95) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL28866728 | 0.92 | APEX1 (0.93) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709874-A1 | MODULATORS OF PROTEIN SECRETION | Sanofi (FR) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231896-A1 | MODULATORS OF PROTEIN SECRETION | SANOFI (FR) | 2024-11-14 | — | — | WO | disclosed |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | PHARNEXT (FR) | 2021-02-02 | — | — | US | disclosed |
| US-10799499-B2 | Combinatorial therapies of neurological disorders | PHARNEXT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20190111054-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2019-04-18 | — | — | US | disclosed |
| CN-109069450-A | The new combination treatment of neurological disorder | 法奈克斯公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3411025-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | Pharnext (FR) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134280-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2017-08-10 | — | — | WO | disclosed |
| EP-3104850-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160354335-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2016-12-08 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | DRD2 1115/4885DRD4 1556/4885DRD3 1620/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | DRD2 4305/4885DRD4 4415/4885DRD3 4363/4885 |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | CPT1B, APOB, GABRB3 | DRD2 1623/4885DRD4 2682/4885DRD3 2024/4885 |
| US-20160354335-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | CPT1B, APOB, GABRB3 | DRD2 1594/4885DRD4 2624/4885DRD3 1954/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | DRD2 2243/4885DRD4 2205/4885DRD3 2501/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | DRD2 647/4885DRD4 737/4885DRD3 922/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885DRD4 1926/4885DRD3 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.